[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100617782":3},{"organization":4,"armGroups":7,"interventions":28,"overallOfficials":33,"centralContacts":43,"locations":49,"responsibleParty":138,"collaborators":33,"id":140,"slug":141,"hasResults":142,"nctId":143,"briefTitle":144,"officialTitle":145,"acronym":33,"eligibilityCriteria":146,"healthyVolunteers":142,"sex":147,"minAge":148,"maxAge":149,"enrollmentInfo":150,"targetDuration":33,"studyType":153,"phases":154,"briefSummary":156,"conditions":157,"keywords":33,"overallStatus":159,"whyStopped":33,"lastUpdateSubmitDate":160,"lastUpdatePostDateStruct":161,"startDateStruct":164,"completionDateStruct":166,"leadSponsor":168,"locationsCount":169},{"fullName":5,"class":6},"Atom Therapeutics Co., Ltd","INDUSTRY",[8,14,18,23],{"label":9,"type":10,"description":11,"interventionNames":12},"ABP-671 plus febuxostat Group 1","ACTIVE_COMPARATOR","Investigators may consider the use of urine alkalinizing agents on an as-needed basis according to the subject's specific condition and standard clinical practice",[13],"Drug: ABP-671 plus febuxostat Group 1",{"label":15,"type":10,"description":11,"interventionNames":16},"ABP-671 plus febuxostat Group 2",[17],"Drug: ABP-671 plus febuxostat Group 2",{"label":19,"type":20,"description":11,"interventionNames":21},"ABP-671 Group","EXPERIMENTAL",[22],"Drug: ABP-671 Group",{"label":24,"type":25,"description":11,"interventionNames":26},"Placebo Group","PLACEBO_COMPARATOR",[27],"Drug: Placebo Group",[29,34,37,40],{"type":30,"name":9,"description":31,"armGroupLabels":32,"otherNames":33},"DRUG","ABP-671 Dose 1 + Febuxostat Dose 1-tablets(PO)",[9],null,{"type":30,"name":15,"description":35,"armGroupLabels":36,"otherNames":33},"ABP-671 Dose 2 + Febuxostat Dose 2-tablets(PO)",[15],{"type":30,"name":19,"description":38,"armGroupLabels":39,"otherNames":33},"ABP-671 Dose 2 + Febuxostat placebo-tablets(PO)",[19],{"type":30,"name":24,"description":41,"armGroupLabels":42,"otherNames":33},"ABP-671 placebo-tablets(PO) + Febuxostat placebo-tablets(PO)",[24],[44],{"name":45,"role":46,"phone":47,"phoneExt":33,"email":48},"Renbo Gao","CONTACT","+86 15062305252","renbo.gao@atombp.com",[50,63,72,81,93,98,103,113,123,133],{"facility":51,"status":33,"city":52,"state":53,"zip":54,"country":55,"countryCode":56,"cosmosGeoPoint":57,"geoPoint":62,"contacts":33},"Renal Research Gosford Pty Ltd","Gosford","New South Wales","2250","Australia","AU",{"type":58,"coordinates":59},"Point",[60,61],151.34399,-33.4244,{"lat":61,"lon":60},{"facility":64,"status":33,"city":65,"state":53,"zip":66,"country":55,"countryCode":56,"cosmosGeoPoint":67,"geoPoint":71,"contacts":33},"Genesis Research services","Newcastle","2019",{"type":58,"coordinates":68},[69,70],151.7801,-32.92953,{"lat":70,"lon":69},{"facility":73,"status":33,"city":74,"state":75,"zip":33,"country":55,"countryCode":56,"cosmosGeoPoint":76,"geoPoint":80,"contacts":33},"Paratus Clinical Research Brisbane","Brisbane","Queensland",{"type":58,"coordinates":77},[78,79],153.02809,-27.46794,{"lat":79,"lon":78},{"facility":82,"status":33,"city":83,"state":84,"zip":85,"country":86,"countryCode":87,"cosmosGeoPoint":88,"geoPoint":92,"contacts":33},"Beijing Tsinghua Changgung Hospital","Beijing","Beijing Municipality","100000","China","CN",{"type":58,"coordinates":89},[90,91],116.39723,39.9075,{"lat":91,"lon":90},{"facility":94,"status":33,"city":83,"state":84,"zip":85,"country":86,"countryCode":87,"cosmosGeoPoint":95,"geoPoint":97,"contacts":33},"Peking University First Hospital",{"type":58,"coordinates":96},[90,91],{"lat":91,"lon":90},{"facility":99,"status":33,"city":83,"state":84,"zip":85,"country":86,"countryCode":87,"cosmosGeoPoint":100,"geoPoint":102,"contacts":33},"Xuanwu Hospital Capital Medical University",{"type":58,"coordinates":101},[90,91],{"lat":91,"lon":90},{"facility":104,"status":33,"city":105,"state":106,"zip":107,"country":86,"countryCode":87,"cosmosGeoPoint":108,"geoPoint":112,"contacts":33},"Jiangsu Province Hospital","Nanjing","Jiangsu","210000",{"type":58,"coordinates":109},[110,111],118.77778,32.06167,{"lat":111,"lon":110},{"facility":114,"status":33,"city":115,"state":116,"zip":117,"country":86,"countryCode":87,"cosmosGeoPoint":118,"geoPoint":122,"contacts":33},"Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine","Shanghai","Shanghai Municipality","200000",{"type":58,"coordinates":119},[120,121],121.45806,31.22222,{"lat":121,"lon":120},{"facility":124,"status":33,"city":125,"state":126,"zip":127,"country":86,"countryCode":87,"cosmosGeoPoint":128,"geoPoint":132,"contacts":33},"Sir Run Run Shaw Hospital , affiliated with the Zhejiang University School of Medicine","Hangzhou","Zhejiang","310000",{"type":58,"coordinates":129},[130,131],120.16142,30.29365,{"lat":131,"lon":130},{"facility":134,"status":33,"city":125,"state":126,"zip":127,"country":86,"countryCode":87,"cosmosGeoPoint":135,"geoPoint":137,"contacts":33},"Zhejiang Provincial People's Hospital",{"type":58,"coordinates":136},[130,131],{"lat":131,"lon":130},{"type":139,"investigatorFullName":33,"investigatorTitle":33,"investigatorAffiliation":33,"oldNameTitle":33,"oldOrganization":33},"SPONSOR","100617782","phase-2-evaluate-the-efficacy-and-safety-of-abp-671-in-subjects-with-chronic-kidney-disease-and-hyperuricaemia-100617782",false,"NCT07323095","Evaluate the Efficacy and Safety of ABP-671 in Subjects With Chronic Kidney Disease and Hyperuricaemia","A Phase 2, International, Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy and Safety of ABP-671 in Subjects With Chronic Kidney Disease and Hyperuricaemia","Inclusion Criteria:\n\n* Male or female aged 18-75 years , who voluntarily participate in this clinical trial, understand and comply with the procedures stipulated in this study\n* Patients who have been diagnosed with CKD based on Clinical Practice Guideline\n* During screening, body mass index (BMI) was ≥18.0 and ≤ 40.0 kg\u002Fm2\n* The sUA levels \\> 420 μmol\u002FL (7.0 mg\u002FdL)\n\nExclusion Criteria:\n\n* History of renal transplantation\n* The 24-hour urinary protein ≥ 3.5 g\u002Fday\n* Liver function abnormality: aspartate aminotransferase or alanine aminotransferase, or alkaline phosphatase \\> 3 times the upper limit of normal value (ULN)\n* Subjects with mental disorders who are unable to communicate normally with the investigator\n* Subjects who have participated in another clinical study during the screening period are within 30 days of the last dose of the study drug in another study\n* The investigator judged that the subject was not suitable for participation in this study","ALL","18 Years","75 Years",{"count":151,"type":152},80,"ESTIMATED","INTERVENTIONAL",[155],"PHASE2","This is a phase 2, international, multicenter, randomized, double blind, placebo-controlled trial to evaluate the efficacy and safety of ABP-671 in subjects with CKD and hyperuricaemia, to preliminarily evaluate the efficacy of ABP-671 in the treatment of subjects with CKD and hyperuricemia, primary Efficacy Endpoint is change in UACR from baseline to Week 40",[158],"Chronic Kidney Disease","NOT_YET_RECRUITING","2026-06-03",{"date":162,"type":163},"2026-06-04","ACTUAL",{"date":165,"type":152},"2026-06-30",{"date":167,"type":152},"2028-01-31",{"name":5,"class":6},10]